Adjusted ICERs for emicizumab prophylaxis among patients with haemophilia A and inhibitors compared with those without prophylaxis in India using the complex adjustment method
| Perspective and age group | Parameter | Emicizumab prophylaxis | No prophylaxis |
| Health system and <12 years | Adjusted cost ($) | 2 862 245 | 4 291 604 |
| Adjusted QALYs | 20.11 | 18 | |
| Incremental adjusted cost ($) | −1 429 359 | – | |
| Incremental adjusted QALYs | 2.11 | – | |
| ICER ($) | Cost saving | – | |
| ICER (₹)* | Cost saving | – | |
| Health system and ≥12 years | Adjusted cost ($) | 2 659 952 | 3 893 373 |
| Adjusted QALYs | 13.6 | 12.79 | |
| Incremental adjusted cost ($) | −1 233 421 | – | |
| Incremental adjusted QALYs | 0.8 | – | |
| ICER ($) | Cost saving | – | |
| ICER (₹)* | Cost saving | – | |
| Societal and <12 years | Adjusted cost ($) | 2 935 463 | 4 386 074 |
| Adjusted QALYs | 20.11 | 18 | |
| Incremental adjusted cost ($) | -1 450 611 | – | |
| Incremental adjusted QALYs | 2.11 | – | |
| ICER ($) | Cost saving | – | |
| ICER (₹)* | Cost saving | – | |
| Societal and ≥12 years | Adjusted cost ($) | 2 715 490 | 3 999 457 |
| Adjusted QALYs | 13.6 | 12.79 | |
| Incremental adjusted cost ($) | −1 283 966 | – | |
| Incremental adjusted QALYs | 0.8 | – | |
| ICER ($) | Cost saving | – | |
| ICER (₹)* | Cost saving | – |
*The exchange rate used was ₹82.25 for US$1, as of 15 May 2023.
ICER, incremental cost-effectiveness ratio; QALY, quality-adjusted life year.